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The cullin 4-RING ubiquitin ligase (CRL4) family employs multiple DDB1–CUL4 associated
factors substrate receptors to direct the degradation of proteins involved in a wide spec-
trum of cellular functions. Aberrant expression of the cullin 4A (CUL4A) gene is found in
many tumor types, while mutations of the cullin 4B (CUL4B) gene are causally associated
with human X-linked mental retardation. This focused review will summarize our current
knowledge of the two CUL4 family members in the pathogenesis of human malignancy
and neuronal disease, and discuss their potential as new targets for cancer prevention and
therapeutic intervention.
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INTRODUCTION
The cullin-RING ubiquitin ligases (CRLs) are the largest E3 lig-
ase family in eukaryotes, and ubiquitinate a wide array of sub-
strates involved in cell cycle, signaling, DNA damage response,
gene expression, chromatin remodeling, and embryonic develop-
ment. Cullins serve as elongated scaffolds that assemble func-
tional E3 complexes by utilizing distinct adaptors to recruit
substrate receptors and the ubiquitin-charged E2 conjugating
enzyme (Figure 1).Within the E2–E3 complex, the RINGdomain-
containing Rbx1/ROC1/Hrt1 or Rbx2/SAG adaptor bridges E2
binding to the cullin carboxyl terminus, which is necessary for
transfer of ubiquitin to all cullin substrates. The cullin amino
terminus binds cullin-speciﬁc adaptors, which in turn recruit dis-
tinct classes of substrate receptors that target substrates to the
E2–CRL complex for ubiquitination and subsequent degradation
by the 26S proteasome. CRL activity is regulated by the Nedd8
post-translational modiﬁcation: the ubiquitin-like Nedd8 pro-
tein is conjugated to cullins in a manner highly analogous to
ubiquitination. In a cascade of events designated the neddylation
cycle, neddylation promotes CRL activity, while deneddylation by
the COP9 signalosome inhibits cullins (reviewed in Petroski and
Deshaies, 2005; Sarikas et al., 2011).
Among the eight cullins (CUL1-7 and PARC) in higher organ-
isms, the CUL4 subfamily of CRLs is uniquely comprised of
two members, CUL4A and CUL4B, that share extensive sequence
homology and functional redundancy. While most cullins recruit
substrate receptors using BTB domain-containing adaptors, the
CUL4 family employs the structurally distinct triple WD40 β-
propeller domain-containing DDB1 adaptor to recruit members
of the DDB1–CUL4 associated factors (DCAF) family of substrate
receptors (Angers et al., 2006; He et al., 2006; Higa et al., 2006a; Jin
et al., 2006; reviewed in Lee and Zhou, 2007). Genetic approaches
have beenutilized to dissect the physiological relevance andunique
functions of the CUL4 family members, as well as the individual
components of the CRL4 ubiquitin ligase complex (Yoon et al.,
2004; Kopanja et al., 2009, 2011; Liu et al., 2009; Yin et al., 2011).
This focused review will summarize recent ﬁndings that have shed
light on the role of CUL4 activity in human disease.
CUL4A AND CANCER
CUL4A was initially identiﬁed as an ampliﬁed or overexpressed
gene in primary human breast cancers (Chen et al., 1998).
Genome-wide analysis of human cancers revealed CUL4A ampli-
ﬁcation in 5% of familial and sporadic breast cancers, and as
high as 20% in the basal-like breast cancer subtype that is
associated with aggressive growth and poor prognosis (Melchor
et al., 2009). CUL4A ampliﬁcation has also been found in squa-
mous cell carcinomas (Shinomiya et al., 1999), adrenocortical
carcinomas (Dohna et al., 2000), childhood medulloblastoma
(Michiels et al., 2002), hepatocellular carcinomas (Yasui et al.,
2002), and primary malignant pleural mesotheliomas (Hung
et al., 2011). Recently, genome-wide high-density SNP arrays
further revealed high CUL4A gene copy number in a subset
of lung and ovarian carcinomas, as well as other solid tumor
types (Beroukhim et al., 2010). Moreover, high CUL4A expres-
sion correlates with signiﬁcantly shorter overall and disease-free
survival (Schindl et al., 2007), indicating that dysregulation of
CUL4A may play a role in promoting oncogenesis. Mouse mod-
els support this hypothesis, as skin-speciﬁc Cul4a knockout mice
showed marked resistance to UV-induced carcinogenesis com-
pared to wild-type and heterozygous mice (Liu et al., 2009).
Transgenic mice with inducible expression of exogenous CUL4A
developed pulmonary hyperplasia, which is consistent with a role
for dysregulated CUL4A in driving uncontrolled proliferation (Li
et al., 2011a). The role of CUL4B in carcinogenesis remains to be
determined.
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FIGURE 1 | Schematic diagram of the multimeric CRL ubiquitin ligase
complex.The elongated cullin scaffold binds cullin-speciﬁc adaptors (CA) at
the N-terminus to recruit substrates (S). All cullins except CUL3 require
separate substrate receptors (SR) to bridge the adaptor–substrate
interaction. RING protein adaptors (R) bind the ubiquitin (Ub)-charged E2
conjugating enzyme at the cullin C-terminus. Nedd8 post-translational
modiﬁcation (N) promotes cullin activity.
The damaged DNA binding proteins DDB1 and DDB2 were
ﬁrst characterized as DNA damage sensors that initiate the
nucleotide excision repair (NER) pathway following UV irradi-
ation (reviewed in Tang and Chu, 2002). Earlier studies identiﬁed
the DDB1–DDB2 heterodimer as both a target and component of
the CRL4 ubiquitin ligase complex (Shiyanov et al., 1999; Chen
et al., 2001; Nag et al., 2001; Groisman et al., 2003). DDB2 muta-
tions that impair the recognition of UV-induced DNA lesions are
causal for the photosensitivity and early onset of skin cancer found
in xeroderma pigmentosumgroupE (XPE) patients (Nichols et al.,
2000), and were recapitulated in the Ddb2 knockout mouse model
(Itoh et al., 2004; Yoon et al., 2004; Alekseev et al., 2005). Con-
versely, enforced expression of DDB2 in transgenic mice delayed
the onset of UV-induced squamous cell carcinomas (Alekseev
et al., 2005), further highlighting the signiﬁcance of DDB2 activity
in DNA repair and cancer prevention. The physiological relevance
of CUL4A-mediated degradation of DDB2 was determined in the
Cul4a knockout mouse, as skin-speciﬁc deletion of CUL4A sig-
niﬁcantly enhanced resistance to UV-induced skin carcinogenesis
(Liu et al., 2009). Protein levels of DDB2 and XPC, another NER
damage sensor and CRL4DDB2 substrate (Sugasawa et al., 2005),
were found to accumulate, thus augmenting NER activity and
decreasing tumorigenic potential.
In addition to DNA repair, CRL4 also plays a signiﬁcant role
in cell cycle regulation by targeting the Cdt1 DNA replication
licensing factor, the p21 cyclin-dependent kinase inhibitor, and
the PR-Set7/Set8 histone H4K20 methyltransferase for ubiquitin-
proteolytic degradation in a Cdt2 (DCAF)- and PCNA-dependent
manner (Higa et al., 2003; Zhong et al., 2003; Hu et al., 2004; Jin
et al., 2006; Nishitani et al., 2006, 2008; Abbas et al., 2008, 2010;
Kim et al., 2008; Centore et al., 2010; Oda et al., 2010; Tardat et al.,
2010; Jorgensen et al., 2011). Knockdown of Cdt2 resulted in G2
arrest and DNA re-replication of the genome (Jin et al., 2006),
indicating a critical role for CRL4Cdt2 in limiting the replication
of DNA during S phase. In response to UV or ionizing radiation,
Cdt1, p21, and PR-Set7/Set8 were rapidly degraded in a CRL4-
dependent manner (Higa et al., 2003; Hu et al., 2004; Abbas et al.,
2008, 2010; Centore et al., 2010; Jorgensen et al., 2011). S phase
arrest is also triggered by CRL4-mediated degradation of Chk1 in
a phosphorylation-dependent manner under normal conditions
and in the presence of genotoxic stress (Zhang et al., 2005; Leung-
Pineda et al., 2009). While these proteins are targeted by both
CUL4 family members, p21 protein levels were found to accumu-
late in primary Cul4a−/− mouse embryonic ﬁbroblasts (MEFs)
following UV irradiation, resulting in prolonged G1/S arrest (Liu
et al., 2009). Higher p21 levels enforced the G1/S cell cycle check-
point post-UV, thus allowing additional time for NER activities to
conclude prior to the initiation of DNA replication. The absence
of G2 arrest or DNA re-replication in the Cul4a knockout mouse
model indicates that CUL4B at least partially compensates for the
loss of CUL4A activity. Simultaneous inactivation of both CUL4A
and CUL4B in primary MEFs led to growth arrest (Liu et al.,
2009), which recapitulates the rapid G1 arrest observed in DDB1
knockout MEF cells (Cang et al., 2006).
Conﬂicting reports indicate that additional cell cycle regulators
may be targeted by CRL4-based ubiquitin ligases for proteasome-
mediated degradation. CUL4Aoverexpression reduced the steady-
state levels of the CDK inhibitor p27Kip1 in 293T cells, while
CUL4A shRNAordominant-negativeCUL4A resulted in the accu-
mulation of p27Kip1 in mouse mammary epithelial cells or the
human MCF-7 breast cancer cell, respectively (Miranda-Carboni
et al., 2008). However, the turnover rate of p27Kip1 was not directly
measured under these conditions. Using primary MEF cells, Cang
et al. (2006) showed that deletion of DDB1 resulted in G1/S
cell cycle arrest and p27Kip1 accumulation. However, the half-
life of p27 was not prolonged in the absence of DDB1, arguing
against p27Kip1 as a direct substrate of the CRL4 ubiquitin ligase.
Future studies should determine whether a CRL4-based E3 ligase
directly or indirectly regulates p27Kip1 protein stability. Interest-
ingly, silencing of CUL4B in primary MEF cells had little effect
on cell proliferation (Liu et al., 2009), but CUL4B knockdown in
HeLa cells resulted in S phase cell cycle arrest (Zou et al., 2007) as
well as cyclin E accumulation (Higa et al., 2006b; Zou et al., 2009).
Given the stimulatory role of cyclin E in S phase progression and
cell proliferation, it remains to be determined how increased cyclin
E levels would result in growth inhibition, and whether additional
CUL4B substrates are also involved in triggering S phase arrest.
The ampliﬁcation or overexpression of CUL4A observed in var-
ious cancers likely correspondswith diminished post-translational
stability of its substrates, many of which are tumor suppressors
(Table 1). CRL4Fbw5 may promote oncogenesis by targeting the
mTOR inhibitor tuberous sclerosis protein 2 (Tsc2) for ubiquiti-
nation (Hu et al., 2008).Mutations in theTsc1 andTsc2 tumor sup-
pressors are causal for the synonymous autosomal dominant dis-
ease that ismarked by the formation of benign growths on the skin,
nervous system, kidneys, and heart. REDD1, another inhibitor of
mTOR signaling, is targeted for degradation by the CRL4βTrCP
ubiquitin ligase (Katiyar et al., 2009). Additional tumor suppres-
sors that are subject to CUL4A-mediated ubiquitination include
p150/Sal2, which is degraded as cells transition from quiescence to
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Table 1 | Involvement of CUL4A substrates in pathogenesis.
DCAF Substrate Substrate functions Associated pathogenesis Reference
DDB2 DDB2 Nucleotide excision repair;
DCAF substrate receptor.
Xeroderma pigmentosum; skin
cancer
Nichols et al. (2000), Chen et al. (2001),
Groisman et al. (2003), Nag et al. (2001),
Sugasawa et al. (2005)
DDB2 XPC Nucleotide excision repair Xeroderma pigmentosum, skin
cancer
Sugasawa et al. (2005)
Cdt2 p21/CIP/WAF1 CDK inhibitor Normal cell cycle and DNA
damage response
Abbas et al. (2008), Kim et al. (2008),
Nishitani et al. (2008)
Cdt2 Cdt1 DNA replication licensing
factor
DNA re-replication Higa et al. (2006a), Jin et al. (2006)
Cdt2 PR-Set7/Set8 Histone methyltransferase Unknown Abbas et al. (2010), Centore et al. (2010),
Jorgensen et al. (2011), Oda et al. (2010),
Tardat et al. (2010)
Fbw5 Tsc2 Inhibitor of mTOR signaling Tuberous sclerosis Hu et al. (2008)
β-TrCP REDD1 Inhibitor of mTOR signaling unknown Katiyar et al. (2009)
RBBP7 p150/Sal2 Inhibitor of cell growth Putative tumor suppressor Sung et al. (2011)
RASSF1A Inhibitor of Ras signaling Putative tumor suppressor Jiang et al. (2011)
TRCP4AP/TRUSS N-Myc, C-Myc Transcription factors Oncoproteins, multiple tumors Choi et al. (2010)
COP1 c-Jun Transcription factor Oncoprotein, multiple tumors Wertz et al. (2004)
COP1 p53 Transcription factor Tumor suppressor Dornan et al. (2004)
COP1 ETV1 Transcription factor Oncoprotein, prostate cancer Vitari et al. (2011)
DCAF1/VprBP unknown Cell cycle regulator Oncoprotein. Inhibited by the
Merlin tumor suppressor
Li et al. (2010)
Cereblon unknown Limb
development/patterning
Terotogenic, multiple myeloma.
Inhibited by thalidomide
Ito et al. (2010)
Unknown HOXA9 Transcription factor Acute myeloid leukemia Zhang et al. (2003)
Unknown p27/Kip1 CDK inhibitor Tumor suppressor Higa et al. (2006b)
Unknown cyclin E Cell cycle progression Oncoprotein, multiple tumors Higa et al. (2006b)
Unknown Chk1 Cell cycle checkpoint
kinase
Tumor suppressor Zhang et al. (2005), Leung-Pineda et al.
(2009), Guervilly et al. (2011)
an actively dividing state (Sung et al., 2011), and RASSF1A (Jiang
et al., 2011), a negative Ras effector that was previously identiﬁed
as a target of the CRL1/SCFSkp2 (Skp1, CUL1, F-box-containing
substrate receptor, and Rbx1) ubiquitin ligase (Song et al., 2008).
Contrary to the trend of CUL4A-mediated degradation of tumor
suppressors, the CRL4 substrate receptor TRCP4AP/TRUSS tar-
gets both N-Myc and C-Myc transcription factors for degrada-
tion (Choi et al., 2010). Stabilization of Myc protein in many
cancer cell lines corresponds with TRCP4AP/TRUSS downreg-
ulation, indicating the potential signiﬁcance of CUL4-mediated
post-translational regulation in restricting Myc protein levels.
COP1, acting as a CRL4 substrate receptor, functions as a tumor
suppressor by targeting the c-Jun proto-oncogene for ubiquitina-
tion (Wertz et al., 2004). However, tissue-speciﬁc differences have
been reported in CRL4-independent COP1 ubiquitin ligase activ-
ity. The p53 tumor suppressor is targeted for degradation by COP1
(Dornan et al., 2004), which may provide mechanistic insight into
COP1 overexpression observed in ovarian and breast cancer. Con-
versely, the oncogenic ETS transcription factors are also degraded
in a COP1-dependent manner, and loss of COP1 activity results in
ETV1 accumulation that promotes prostate epithelial cell prolif-
eration (Vitari et al., 2011). Finally, ectopic expression of CUL4A
in PC12 rat pheochromocytoma cells suppresses apoptosis and
promotes cell survival (Tan et al., 2011), further indicating that
CUL4A activity supports cell growth.
The oncogenic effects of CUL4A are highlighted by the ﬁnding
thatMerlin, a tumor suppressor encodedbyNF2, inhibits the ubiq-
uitin ligase activity of CUL4A in complex with VprBP/DCAF1 (Li
et al., 2010). Moreover, mutations in Merlin that ablate the enzy-
matic inhibition of CRL4VprBP have been found in patients with
the neuroﬁbromatosis type 2 familial cancer syndrome (Li et al.,
2010). VprBP silencing compromises tumorigenesis in Merlin-
deﬁcient mesothelioma cell lines, indicating the signiﬁcance of
CRL4VprBP signaling in promoting cellular proliferation (Li et al.,
2010). Huang and Chen showed that Merlin was targeted for
degradation by the CRL4VprBP ubiquitin ligase (Huang and Chen,
2008). However, Li et al. demonstrated that Merlin was not a sub-
strate of CRL4VprBP, but rather served as a negative regulator of the
CRL4VprBP ubiquitin ligase. Further biochemical and genetic stud-
ies are required to determine the functional relationship between
Merlin and CRL4VprBP. VprBP is also required for cell cycle pro-
gression into S phase (Belzile et al., 2007; Hrecka et al., 2007; Le
Rouzic et al., 2007; Tan et al., 2007;Wen et al., 2007), but the mech-
anism of cell cycle regulation and the cellular targets of CRL4VprBP
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have yet to be determined. Nevertheless, these ﬁndings indicate a
role for the CRL4VprBP ubiquitin ligase in promoting cell cycle
progression and oncogenic transformation.
Despite the numerous growth-promoting pathways that are
ampliﬁed by CUL4A activity, the degradation of other identiﬁed
CUL4A substrates reveals a more complex effect on growth reg-
ulation. CUL4A plays a critical role in granulopoiesis by degrad-
ing the HOXA9 homeodomain protein, which may also restrict
HOXA9-induced leukemogenesis (Zhang et al., 2003). The leuke-
mogenic NUP98–HOXA9 fusion protein, which is derived from
the t (9;11)(p15;p15) chromosomal translocation in acute myeloid
leukemia patients, is resistant to CUL4A-mediated degradation,
further indicating that CUL4A may play a role in the proper differ-
entiation of hematopoietic cells (Chung et al., 2006). In addition to
restricting the NER threshold, CRL4 also responds to DNA dam-
age through histone H3 and H4 ubiquitination, which facilitates
the recruitment of repair proteins (e.g., XPC) to damaged DNA
(Wang et al., 2006). Thus, the CUL4A ubiquitin ligase may play
distinct roles in tumorigenesis that are dictated by cellular context
or environmental conditions.
CUL4B AND HUMAN X-LINKED MENTAL RETARDATION
CUL4B mutations in human patients have been found to be causal
for X-linked mental retardation (XLMR) syndrome (Tarpey et al.,
2007; Zou et al., 2007; Badura-Stronka et al., 2010; Isidor et al.,
2010). Patient-derived cells also display increased camptothecin-
induced topoisomerase I-dependent DNA breaks, which are asso-
ciated with the peripheral neuropathy spinocerebellar ataxia with
axonal neuropathy-1 (SCAN-1; Kerzendorfer et al., 2010). The
unique CUL4B N-terminus may mediate the recruitment of dis-
tinct substrates for degradation, and their accumulation likely
contributes to the CUL4B phenotype. WDR5, a subunit of the
H3K4 methyltransferase complex, was initially identiﬁed as a
DCAF and more recently characterized as a CUL4B substrate
(Nakagawa and Xiong, 2011). XLMR-derived CUL4B mutations
resulted in the accumulation of WDR5 and subsequent activation
of neuronal genes that promote neurite extension. Peroxiredoxin
III is another unique CUL4B substrate that may affect neural
development through the regulation of reactive oxygen species
(ROS) levels (Li et al., 2011b). Finally, the arylhydrocarbon recep-
tor (AhR) acts as a unique CUL4B substrate receptor that targets
estrogen and androgen receptors for proteasome-mediated degra-
dation (Ohtake et al., 2007), further highlighting the role of CUL4B
as a transcriptional regulator.
Distinct expression patterns may also account for the pheno-
types observed in the Cul4a knockout mouse model. In addition
to enhanced resistance against UV-induced skin carcinogenesis,
CUL4A knockout also resulted in male infertility (Kopanja et al.,
2011; Yin et al., 2011). These studies revealed non-overlapping
expression patterns between CUL4A and CUL4B during the
pachytene to diplotene stages in adult testes, thus accounting for
the physiological requirement for CUL4A activity in spermato-
genesis (Yin et al., 2011). The disease syndrome manifested in
humans with CUL4B mutations may be attributed to exclusive
substrate targeting and/or differential expression patterns of the
CUL4 family members. In vivo interrogation of CUL4B activ-
ity using knockout mouse models would shed insight into the
mechanismof pathology, andmay identify avenues for therapeutic
intervention.
CRL4 AS A CANDIDATE FOR THERAPEUTIC INTERVENTION
Manipulation of the post-translational stability of cellular proteins
has been demonstrated to be a new and effective cancer thera-
peutic strategy. Proteasome inhibitors, such as bortezomib, non-
speciﬁcally block the overall degradation of poly-ubiquitinated
proteins, but preferentially sensitize rapidly dividing cells to apop-
tosis (Richardson et al., 2003;Kane et al., 2007;Orlowski andKuhn,
2008). MLN4924, a small molecule inhibitor of the Nedd8 E1 acti-
vating enzyme, speciﬁcally blocks cullin activity, which leads to
the accumulation of their substrates (Soucy et al., 2009). However,
more precise targeting of CRL complexes has been shown to be
possible with the discovery that the teratogenic agent thalidomide
speciﬁcally inhibits Cereblon (CRBN) (Ito et al., 2010), an iden-
tiﬁed DCAF for the CRL4 ubiquitin ligase family. Substrates for
CRL4CRBN have yet to be determined, but aberrant Fgf8 expres-
sion and signaling were observed following Cereblon inhibition
(Ito et al., 2010). Thalidomide is currently used to treat multiple
myeloma, indicating that Cereblon activity likely promotes cell
growth.
Viral hijack of CRL4 activity may provide further insight into
possible mechanisms of CRL4 intervention. Parainﬂuenza virus
5 (PIV5, formerly SV5) V protein binds DDB1, which recruits
STAT2 to target STAT1 for ubiquitination and proteasome-
mediated degradation, thus inhibiting the cellular interferon-
induced response to viral infection (Precious et al., 2005, 2007).
Additional rubulaviruses, such as human parainﬂuenza virus 2
and mumps virus, also target STAT proteins for degradation by
redirecting DDB1 activity through their V proteins (Ulane and
Horvath, 2002). DDB1 binding by the hepatitis B virus X protein
(HBx) resulted in S phase arrest (Martin-Lluesma et al., 2008), and
the subsequent deleterious effects contributed to hepatocellular
carcinomas in a cell-non-autonomous manner that was recapit-
ulated in hepatocyte-speciﬁc Ddb1 knockout mice (Yamaji et al.,
2010). S phase arrest is also triggered by HIV-1 Vpr and HIV-
2 Vpx proteins through CRL4VprBP binding, which may promote
macrophage infection (Shariﬁ et al., 2012). Thus, the modiﬁcation
of DDB1 substrate binding represents another method of altering
CRL4 activity for therapeutic purposes.
CONCLUDING REMARKS
Despite the signiﬁcant sequence conservation and functional
redundancy of the CUL4 family members, CUL4A and CUL4B
play strikingly diverse roles in human disease. CUL4A activity pro-
motes oncogenesis, as demonstrated by the overexpression and/or
ampliﬁcation of CUL4A in several tumor types and the resistance
to UV-induced skin carcinogenesis in the Cul4a knockout mouse
model, while loss-of-function mutations in CUL4B are causal
for human X-linked mental retardation syndrome. Surprisingly,
gene-trapped inactivation of Cul4b in mice resulted in embryonic
lethality (Cox et al., 2010). The genetic interrogation of CUL4B
awaits the generation of a conditional Cul4b knockout mouse
model to identify the unique in vivo contributions of CUL4B
activity, and the major substrates that are responsible for CUL4B-
dependent disease phenotypes. Furthermore, additional mouse
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models are required to gain a comprehensive understanding of the
role of CRL4 in pathogenesis through the functional delineation
of the DCAF substrate receptors, their substrates (Emanuele et al.,
2011), and the associated cellular pathways whose dysregulation
contribute to pathogenesis.
CUL4A represents an ideal target for therapeutic intervention,
as genetic ablation in mice resulted in a marked resistance to car-
cinogenesis. Additionally, the recent structural determination of
CRL4 assembly and activation provides a molecular platform for
the design of inhibitors (Angers et al., 2006; Li et al., 2006; Fis-
cher et al., 2011). Although the extensive protein–protein interface
between CUL4 and DDB1 may present a formidable challenge
for direct intervention by small molecule inhibitors, allosteric
inhibitors are an attractive alternative to attenuate CRL4 activ-
ity, especially given the stringent requirements of proximity and
E2–E3orientation for effective ubiquitin transfer. Finally, the strik-
ing efﬁcacy of thalidomide in treating multiple myeloma and its
inhibition of Cereblon activity indicate that developing speciﬁc
inhibitors for multiple subunits or interfaces, e.g., DCAF binding
to either CRL4 or substrates, may prove to be feasible therapeutic
strategies.
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